跳至主要内容
临床试验/NCT00961532
NCT00961532已完成2 期

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Northwestern University1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
14
试验地点
1
主要终点
Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment

研究概览

简要总结

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Spontaneous intracerebral hemorrhage as documented by head CT scan
  • Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

排除标准

  • International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
  • History of von Willebrand disease
  • Pregnancy
  • Known hypersensitivity to DDAVP or desmopressin
  • Active cardiovascular disease or unstable angina
  • Hyponatremia or history of hyponatremia
  • Current or historical deep venous thrombosis or pulmonary embolism

研究组 & 干预措施

DDAVP

Experimental

DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes

干预措施: DDAVP injection (desmopressin acetate) (Drug)

结局指标

主要结局

Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment

时间窗: 60 minutes after treatment start

The Platelet Function Analyzer (PFA) is a commercially available point-of-care assay that measures the time to closure of an aperature. Longer time to closure indicates less platelet activity. EPI denotes epinephrine (as opposed to adenosine diphosphate) as the stimulant to platelet aggregation. In our laboratory, a time to closure of at least 172 seconds in consistent with an aspirin effect.

次要结局

  • Adverse Events : New Fever >=100.4F, Respiratory Distress or Pulmonary Edema on Chest Radiography, Rash, Hypotension (Systolic BP < 100 mm Hg or New Vasopressor Use or Increase in Vasopressor Dose by >25%)(within 6 hours of study treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew Naidech

Associate Professor

Northwestern University

研究点 (1)

Loading locations...

相似试验